Finch D R, Morris P J
Transplantation. 1976 Nov;22(5):508-12. doi: 10.1097/00007890-197611000-00015.
Pancreatic islets from DA, Lewis, or DA X Lewis F1 rats were transplanted into the portal vein of Lewis or DA recipients made diabetic by prior treatment with Streptozotocin. The islets corrected the hyperglycaemia within 48 hr but were rejected within 5 days in all combinations. Passive enhancement of homozygous Lewis or DA islets with Lewis anti-DA or DA anti-Lewis antiserum in a single dose of 500 mul delayed rejection for several days, but where DA X Lewis F1 islets were used, rejection was delayed markedly with two of five animals in both the DA X Lewis F1 to DA and in DA microliters and 2.5 ml of enhancing serum were less effective than 500 mul in suppressing rejection. Thus, passive enhancement of allogeneic pancreatic islets was extremely effective in suppressing or delaying rejection of DA X Lewis F1 islets but was able to delay rejection of homozygous pancreatic islets by only a few days.
将来自DA、Lewis或DA×Lewis F1大鼠的胰岛移植到经链脲佐菌素预先处理致糖尿病的Lewis或DA受体的门静脉中。胰岛在48小时内纠正了高血糖，但在所有组合中均在5天内被排斥。用500微升单剂量的Lewis抗DA或DA抗Lewis抗血清对纯合Lewis或DA胰岛进行被动增强，可使排斥延迟数天，但当使用DA×Lewis F1胰岛时，在DA×Lewis F1到DA以及DA×Lewis F1到Lewis的移植中，五只动物中有两只的排斥明显延迟，且2.5毫升增强血清在抑制排斥方面不如500微升有效。因此，同种异体胰岛的被动增强在抑制或延迟DA×Lewis F1胰岛的排斥方面极其有效，但仅能将纯合胰岛的排斥延迟几天。
